News
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pfizer Completes Acquisition of Global Blood Therapeutics
Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven
Inogen to Announce Third Quarter 2022 Financial Results on November 2, 2022
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will issue third quarter 2022 financial results
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Availability of Poxel's 2022 Half-Year Financial Report
POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including
EQS-Adhoc: Heidelberg Pharma AG Announces Adjustment of Guidance
Premier, Inc. to Report Fiscal 2023 First-Quarter Results and Host Conference Call on November 1, 2022
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 first quarter on Tuesday, November 1, 2022, at approximately 6:30 a.m. ET. The company will
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy
EQS-News: ABIVAX ANNOUNCES AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING ON NOVEMBER 9, 2022
Pharnext announces a reverse stock split and suspension of the right to exercise all the securities giving access to Pharnext's share capital including the conversions of convertible bonds
Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A
Vistagen to Participate at Cantor Neurology & Psychiatry Conference
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Novocure to Report Third Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open. Novocure management
Agilent Announces Enhanced 8700 LDIR Chemical Imaging System for Microplastics Analysis
Agilent Technologies Inc. (NYSE: A) today announced the release of its enhanced 8700 LDIR Chemical Imaging System, which has been further optimized for the analysis of microplastics in
TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the Phase 3, open-label, multicenter, randomized TRITON3 trial demonstrating that Rubraca monotherapy treatment
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc